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Diffuse panbronchiolitis (DPB) is an idiopathic inflammatory disease that seems to have an immunological
pathogenesis and that causes a severe progressive suppurative and obstructive respiratory disorder. Common
variable immunodeficiency (CVID) is the most common serious primary immunodeficiency and it is often associated
with respiratory diseases. Herein, we describe a case of DPB in a 41-year-old man affected by CVID. We examined
the patient’s lungs, focusing on the characteristics of the inflammatory cells and of the foamy macrophagic nodules
typical of DPB. Immunohistochemical typing of the lymphocytic infiltrate showed that B-cells were almost absent,
matching the immunological profile of CVID. The case described is the first case reported in the literature of DPB in
a patient affected by CVID. Moreover it seems to confirm the correlation between an immunodeficiency status and
the development of DPB and provides more information on the accumulation of nodules of foamy macrophages in
DPB.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/5310709471138338.
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Diffuse panbronchiolitis (DPB) is an idiopathic inflam-
matory disease that is characterized by progressive
suppurative and obstructive airway disease, which, if left
untreated, gives rise to bronchiectases, respiratory failure
and death [1]. Chronic pulmonary obstructive disease
(COPD) is characterized by irreversible airflow limitation
and abnormal inflammatory response to noxious gases,
especially cigarette smoke [2]. Many pathogenetic mech-
anisms seem to be involved in the development of
COPD, including delayed apoptosis of neutrophils [2],
aberrant methylation of tumor suppressor genes [3] and
an immune-modulatory role of surfactant proteins such
as pulmonary haptoglobin [4]. DPB was proposed as a
disease entity, distinct from COPD, by Homma and* Correspondence: ginori@student.unisi.it
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stated.Yamanaka in the 1960s in Japan, but it was not inter-
nationally accepted until the 1980s [5]. The term “dif-
fuse” refers to the distribution of the lesions throughout
both lungs, and the term “pan-” refers to the inflamma-
tion which involves all the layers of the respiratory
bronchioles [6]. Outside Asia, only a limited number of
cases have been reported. The prevalence of clinician-
diagnosed DPB is 11 cases per 100,000 people [7], with
a male to female ratio of 1.4 to 1 and a median age of
40-60 years. Patients suffer from chronic bacterial infec-
tion due to Haemophilus influenzae, Streptococcus pneu-
moniae and other species in the airways. Bacteria in the
airway are gradually replaced by Pseudomonas aerugi-
nosa and the disease is progressive in nature [8]. The
prognosis of patients with DPB was poor, with 5- and
10-year survival rates of 62.1 and 33.2%, respectively.
However, long-term treatment with erythromycin has in-
creased the 10-year survival rate to >90% [6]. Although
nothing is known about the aetiology of this disease, thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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grants, led to the suggestion that there could be a major
susceptibility gene for DPB, located between the Human
Leukocyte Antigen (HLA)-A and HLA-B loci [8]. More-
over, DPB has also been compared and associated with
cystic fibrosis (CF), bare lymphocyte syndrome (BLS)
type I, human T-cell lymphotropic virus type 1 (HTLV-1)
and rheumatoid arthritis [6,9]. Common variable immu-
nodeficiency (CVID) is the most common severe primary
immunodeficiency with a reported prevalence of 1:30,000.
CVID is a diagnosis of exclusion based on the presence
of hypogammaglobulinaemia of at least two immuno-
globulin isotypes, recurrent sinopulmonary infections,
and impaired functional antibody responses, that include
absent isohaemagglutinins, poor responses to protein
or polysaccharide vaccines, or both [10]. The cellular char-
acteristics of the immune system in CVID are complex
with several numerical and functional defects involving
both B and T lymphocytes, natural killer cells, macro-
phages and monocytes. In patients with CVID, respiratory
diseases are a significant cause of morbidity and mortality.
Histologic studies revealed that interstitial lung disease
(ILD) in the context of CVID may manifest as sarcoid-like
granuloma, organizing pneumonia, nonspecific interstitial
pneumonia (NSIP), follicular bronchiolitis and lympho-
cytic interstitial pneumonia (LIP). These different patterns
may be found in adjacent zones or even intermingled
within one lung specimen [11]. In particular, LIP and
follicular bronchiolitis belong to the same spectrum of
benign lymphoproliferative disorders of the lungs [12]
and often co-exist in CVID with pulmonary granuloma-
tous diseases. For this reason they have recently been
grouped together under the term granulomatous lympho-
cytic interstitial lung disease (GLILD) [13]. Herein, we
present a case of DPB in a man affected by CVID, and
a pathogenetic correlation between these two entities is
hypothesized. To the best of our knowledge, the associ-
ation between DPB and CVID has never been described
in the literature.
Case presentation
Clinical summary
A 41-year-old Caucasian man, never smoker, had been re-
ferred to the Respiratory Diseases and Lung Transplant-
ation Unit of our Hospital to be evaluated for lung
transplantation because of chronic respiratory failure sec-
ondary to chronic lung disease and CVID. Diagnosis of
CVID had been made when the patient was 22 years old
for recurrent respiratory tract infections; he had a
complete deficiency of the production of all immuno-
globulin classes (IgA, IgM, IgG and IgE). He worked in
textile industry until the age of 38 when he developed
chronic respiratory failure and started oxygen-therapy.
At 33 years old he had also been diagnosed withundifferentiated spondyloarthritis, treated with low dose
of steroids. Chronic infection of respiratory tract by Hae-
mophilus influenzae was present from the age of 24 and
fifteen years later also Streptococcus pneumoniae was iso-
lated in his sputum. When the patient came to our obser-
vation, he was on 24 h oxygen-therapy for type I chronic
respiratory failure (blood gas analysis showed pH 7,40,
pO2 66 mmHg, pCO2 38 mmHg, HCO3- 22 mmol/L
with O2-therapy 2 L/min with nasal cannula). He was in
New York Heart Association (NYHA) functional class III
and pulmonary function tests showed a very severe ob-
structive respiratory deficiency with marked increase of
static pulmonary volumes (FVC: 1180 ml, 25,2%; FEV1:
540 ml, 13,9%; FEV1/FVC ratio: 45%, RV: 9360 ml, 482%;
TLC: 11170 ml, 161%). At chest auscultation bilateral
crackles and wheezes were present. All the microbiologic
examinations and PCR detection of most common re-
spiratory viruses (including HTLV-1) were negative. A
chest High Resolution Computed Tomography (HRCT)-
scan showed mild bilateral dilatation of airways, bronchial
wall thickening and a centrilobular distribution of nodular
shadows, often extending to small, branching linear areas
of attenuation (“tree-in-bud” pattern), predominantly in
the middle and upper fields, consistent with bronchiolitis
(Figure 1A). Panlobular emphysema was present in the
lower lobes. Interestingly, HRCT alterations were moder-
ate in contrast to respiratory impairment as documented
by clinical and functional findings. Peripheral immuno-
phenotype showed increased circulating T lymphocytes
(94%) with conserved CD4/CD8 ratio, reduction of NK
lymphocytes (3%) and total absence of B-lymphocytes.
Serum IgA, IgM, IgG and IgE were undetectable. HLA
typing showed positivity for HLA-A*01, HLA-A*11, HLA-
B*51, HLA-B*52, DRB1*12 and DRB1*15. The patient was
listed for lung transplantation and 8 months later he
underwent bilateral lung transplantation.
Pathologic findings
Lung tissue was fixed in 10% neutral buffered formalin. At
gross examination, the lungs showed multiple bilateral
white-yellowish small nodules, 2-5 mm in diameter,
centred on small airways, more frequently in the upper
lobes, associated with bronchiectases (Figure 1B-D).
Representative samples were taken and paraffin embed-
ded. Four micrometer-thick sections were stained with
haematoxylin and eosin (HE) and examined by light mi-
croscopy. Histologically, transmural and peribronchial
infiltration by lymphoctytes and histiocytes was found,
with prominent involvement of respiratory and terminal
bronchioles. The inflammatory infiltrate showed a char-
acteristic topography: the bronchiolar lumen contained
neutrophils, while the peribronchiolar infiltrate was con-
stituted of an inner layer of lymphocytes and an outer
layer of histiocytes. Most of the histiocytes were foamy
Figure 1 Chest HRCT scan and gross examination of the lungs. (A) HRCT scan: nodular shadows were distributed in a centrilobular fashion,
often extending to small branching linear areas of attenuation (“tree-in-bud” pattern); (B-D) gross examination of the lungs showed bilateral
multiple white-yellowish small nodules centred on small airways.
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cially in the wall of respiratory bronchioles, in the sur-
rounding interalveolar septa and around the blood and
lymphatic vessels. In some areas, the acute inflammatory
infiltrate destroyed the bronchiolar epithelium and ex-
tended to the peribronchiolar spaces, with distortion of
the alveolar structure and formation of microabscesses.
A severe peribronchial and peribronchiolar fibrosis was
also seen (Figure 2A-F). Gram and Grocott stains were
negative for bacterial and fungal microorganisms. Immu-
nohistochemical stains showed that CD79a + and CD20+
B-cells were almost absent (Figure 3A-B) and that there
was a heterogeneous population of CD4+ and CD8+ T-
cells in the lymphocytic infiltrate (Figure 3C-D). The
histiocytes expressed CD68, and there was a discrete
number of CD1a + cells. There were no signs of GLILD.
Upon examination of the histological slides at polarized
light microscope, there were no traces of extrapulmon-
ary fibers. The final diagnosis, according also to the
radiological and clinical findings and to the clinical his-
tory of the patient, was acute necrotizing and chronic
fibrosing panbronchitis and panbronchiolitis.
Discussion
To the best of our knowledge, the case reported herein is
the first case described in the literature of panbronchiolitisin a patient affected by CVID. The development of granu-
lomatous disease or auto-immunity in CVID are two of
the most problematic clinical complications [14]. Al-
though granulomas can be found in many organs, lungs
are the most frequent and relevant location [15]. In some
patients an intense lymphoid infiltrate is associated with
granulomas, realizing what has been termed GLILD [13].
DPB is a rare disease characterized by chronic inflamma-
tion of respiratory bronchioles and sinobronchial infection
[8]. Inflammatory nodular lesions around the bronchioles
occur diffusely throughout the lungs. Histopathologically,
the nodules consist of lymphocytes and foamy macro-
phages around respiratory bronchioles. Interstitial accu-
mulations of foamy macrophages in the wall of respiratory
bronchioles and in the surrounding interalveolar septa
represent peculiar histological features of DPB. The bron-
chiolar lumen contains neutrophils. Lymphoid follicles
along the airways are also frequently noted. The inflam-
matory infiltrate destroys the bronchiolar epithelium
and extends to peribronchiolar spaces. The cause of dif-
fuse panbronchiolitis is still unknown, although it is
reasonable to think that environmental factors and gen-
etic susceptibility contribute to the development of the
disease. Immunogenetic studies revealed a strong asso-
ciation with HLA-B54 in Japanese, whereas an associ-
ation with HLA-A11 was reported in Koreans [8].
Figure 2 Histological features. (A-D) Transmural and peribronchial infiltration by lymphoctytes and histiocytes was found, with prominent and
diffuse involvement of respiratory and terminal bronchioles; most of the histiocytes were foamy macrophages, which formed “nodules”,
distributed especially in the wall of respiratory bronchioles, in the surrounding interalveolar septa and around the blood and lymphatic vessels.
HE, x25. (E) The inflammatory infiltrate showed a characteristic topography: the bronchiolar lumen contained neutrophils, while the
peribronchiolar infiltrate was constituted of an inner layer of lymphocytes and an outer layer of histiocytes. HE, x200. (F) Note the exuberant
perivascular distribution of foamy macrophages. HE, x200.
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cells, together with the cytokines interleukin (IL)-8 and
macrophage inflammatory protein-1 are believed to
play key roles in the development of DPB. Previous re-
ports have suggested that the accumulation of neutro-
phils and IL-8 secretion in the airway lumen plays an
important role in the pathogenesis of the disease [16].
It is possible to speculate that neutrophil chemotacticfactors at the site of inflammation and upregulation of
adhesion molecules in the circulation can promote the
entry of neutrophils into the airways. The accumulation
of activated neutrophils in the airways may damage
epithelial cells, by releasing oxidative and proteolytic
products, and promote the development of extensive
bronchiectases [6]. The pathogenetic significance of
bronchus-associated lymphoid tissue (BALT) is less
Figure 3 Immunohistochemical stains. (A-B) CD20+ B-cells were almost absent in the lymphocytic infiltrate; (C-D) a heterogeneous population
of CD4+ and CD8+ T-cells was present.
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ber, of CD3+ cells. In addition, a significant increase
both in the percentage and in the absolute number of
activated CD8+ cells has been observed [17]. The num-
ber of CD4+ cells is also increased [18]. A marked in-
creases of the number of dendritic cells (DCs), as in
our case, is found in both the bronchiolar epithelium
and in submucosal tissues of patients with DPB. The
observed increase and activation of DCs in DPB may
support an enhanced immune response around the
bronchioles through the promotion of antigen presen-
tation [19]. The increase of foamy cells is considered a
consequence of an abnormal uptake of surfactant pro-
teins by macrophages, caused by airway obstruction or
metabolic impairment [20]. However, the interstitial lo-
cation of foamy macrophages renders these causes un-
likely. The hypothesis that a disorder of the immune
system is implicated in the pathogenesis and the devel-
opment of DPB is also supported by the association of
DPB with other conditions as CF, BLS, HTLV-1 infec-
tion and rheumatoid arthritis [6]. In our patient, PCR
detection of most common respiratory viruses (includ-
ing HTLV-1) was negative. Our case is different from
the cases of DPB previously reported in the literature
because there is no lymphoid hyperplasia and the nod-
ules of foamy macrophages are more numerous and
present both in perivascular and interstitial tissues.
Moreover, there are neither sign of GLILD nor of theother granulomatous lesions described in literature in
patients affected by CVID. In our case, a not yet identi-
fied trigger, probably of infectious origin, caused the ac-
cumulation of activated neutrophils in the airways,
leading to a sequential activation of inflammatory path-
ways. In our patient, the reduced B-cell immunocompe-
tence probably played an important role in the
activation of an alternative immune response, charac-
terized by CD4+ and CD8+ T-cells and also involving
activated macrophages. According to our findings, the
formation of nodules of foamy macrophages does not
seem to depend on lymphoid hyperplasia, which is ab-
sent in our case, but probably depends on an insuffi-
cient or altered B or T lymphocytic response. Thus, the
B-lymphocytic deficiency in our DPB would have led to
an increase of nodules of foamy macrophages, involving
also the peribronchial lymphatic and haematic vessels.
Conclusions
The case described herein is interesting not only because
it is the first case of DPB in a patient affected by CVID
reported in the literature, but also because it further
supports the heterogeneity of the clinical manifestations
of CVID. It seems to confirm the correlation between an
immunodeficiency status and the development of DPB.
It provides more information on the accumulation of
nodules of foamy macrophages in DPB, but further stud-
ies are needed to better understand the pathogenesis of
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However, it should be remembered that in cases like that
reported herein an interdisciplinary case evaluation is
necessary to find correct diagnoses [21].Consent
Written informed consent was obtained from the patient
for publication of this Case Report and any all accom-
panying images. A copy of the written consent is avail-
able for review by the Editor-in-Chief of this journal.
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